 Novus Therapeutics, Inc. NVUS, a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat ENT, today announced that the U.S. Food and Drug Administration FDA has agreed with the Companys proposed patient population, endpoints, and statistical analysis plan for a phase 2a study of OP0201 in patients with chronic otitis media with effusion COME study C-009. The FDAs feedback on the study C-009 was detailed in the minutes from a Type C meeting held with the Companys management team on September 20, 2019. Study C-009 is designed to explore the effect of daily administration of OP0201 in patients with COME, a non-infectious form of otitis media. 